PDCD1 and synovial sarcoma: Other antibodies are currently being investigated for treating MF/SS patients, such as pembrolizumab (an immune checkpoint inhibitor that blocks PD-1) and lacutamab (IPH4102; an anti-KIR3DL2 monoclonal antibody).